Test can identify patients in intensive care at greatest risk of life-threatening infections

June 13, 2018, University of Cambridge

Patients in intensive care units are at significant risk of potentially life-threatening secondary infections, including from antibiotic-resistant bacteria such as MRSA and C. difficile. Now, a new test could identify those at greatest risk – and speed up the development of new therapies to help at-risk patients.

Infections in intensive care units (ICU) tend to be caused by organisms, such as multi-resistant gram-negative bacteria found in the gut, that are resistant to frontline antibiotics. Treating such infections means relying on broad spectrum antibiotics, which run the risk of breeding further drug-resistance, or antibiotics that have toxic side-effects.

Estimates of the proportion of patients in ICU who will develop a secondary range from one in three to one in two; around a half of these will be pneumonia. However, some people are more susceptible than others to such infections – evidence suggests that the key may lie in malfunction of the immune system.

In a study published in the journal Intensive Care Medicine, a team of researchers working across four sites in Edinburgh, Sunderland and London, has identified markers on three immune cells that correlate with an increased risk of secondary infection. The team was led by researchers at the Universities of Cambridge and Edinburgh and biotech company BD Bioscience.

"These markers help us create a 'risk profile' for an individual," explains Dr. Andrew Conway Morris from the Department of Medicine at the University of Cambridge. "This tells us who is at greatest risk of developing a secondary infection.

"In the long term, this will help us target therapies at those most at risk, but it will be immediately useful in helping identify individuals to take part in clinical trials of new treatments."

Clinical trials for interventions to prevent secondary infections have met with mixed success, in part because it has been difficult to identify and recruit those patients who are most susceptible, say the researchers. Using this new test should help fine tune the selection of clinical trial participants and improve the trials' chances of success.

The markers identified are found on the surface of key immune cells: neutrophils (frontline immune cells that attack invading pathogens), T-cells (part of our adaptive immune system that seek and destroy previously-encountered pathogens), and monocytes (a type of white blood cell).

The researchers tested the correlation of the presence of these markers with susceptibility to a number of bacterial and fungal infections. An individual who tests positive for all three markers would be at two to three times greater risk of secondary infection compared with someone who tests negative for the markers.

The markers do not indicate which secondary infection an individual might get, but rather that they are more susceptible in general.

"As specialists, our priority is to prevent patients developing secondary infections and, if they do, to ensure they get the best treatment," says Professor Tim Walsh from the University of Edinburgh, senior author on the study.

The Immune Failure in Critical Therapy (INFECT)Studyexamined data from 138 individuals in ICUs and replicated findings from a pilot study in 2013.

A key part of enabling this study was to standardise how the research could be carried out across multiple sites, say the researchers. They used an imaging technique known as flow cytometry, which involves labelling components of the cells with fluorescent markers and then shining a laser on them such that they give off light at different wavelengths. This has previously been difficult to standardise, but the researchers successfully developed a protocol for use, ensuring they could recruit from the four study sites.

Explore further: Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens

More information: Andrew Conway Morris et al. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study, Intensive Care Medicine (2018). DOI: 10.1007/s00134-018-5247-0

Related Stories

Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens

April 22, 2018
The antibiotic combination treatment piperacillin-tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI) caused by ceftriaxone-resistant Escherichia coli and ...

Scientists find potential mechanism for deadly, sepsis-induced secondary infection

September 14, 2017
In mice, an infection-induced condition known as sepsis may increase the risk of life-threatening secondary infection by preventing recruitment of infection-fighting cells to the skin, according to new research published ...

A third of bacterial infections in patients with cirrhosis across the world are multi-drug resistant

April 12, 2018
A worldwide study initiated to investigate the epidemiology and outcomes of bacterial infections in hospitalized patients with liver cirrhosis has reported a prevalence of multi-drug-resistant (MDR) bacteria of 34% and significant ...

New way to fight sepsis: Rev up patients' immune systems

March 8, 2018
While many people have never heard of sepsis, it causes about 250,000 deaths annually in the United States. The condition develops when an infection triggers an overwhelming immune response, ultimately wreaking havoc on the ...

New flu test: One drop of blood could save your life

June 15, 2017
Australian researchers have developed a world first test to identify which influenza patients will need urgent, life-saving, medical treatment.

Immune discovery points to therapies to improve stroke recovery

April 20, 2017
Having a stroke damages immune cells as well as affecting the brain, research has found.

Recommended for you

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.